Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet (PODD – Research Report), with a price target ...

Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Investors interested in Medical - Products stocks are likely familiar with ResMed (RMD) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks ...

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...